“…We followed up all 32 patients in our study. The median DFI was 15 months from the time of the primary operation, and the median survival time was 31 months, similar to the reported studies [36]. Belforie et al [19] reported cancer-specific mortalities of 69%, 54% and 49% at 1, 2 and 3 years in 56 patients treated with MWA.…”
Section: Discussionsupporting
confidence: 83%
“…In the present study, the 1-, 2-and 3-year survival rates were 79.5%, 63.1% and 44.4%, respectively. Reported independent predictors of OS include location of primary disease for lung metastasis [37], tumour stage [36], number of metastases [37], tumour size [20,36,37] and extrapulmonary metastasis [38]. In the present study, multivariate analysis showed that tumour size was an independent prognostic factor for survival.…”
Section: Discussionsupporting
confidence: 51%
“…Previous studies have shown that MWA therapy can improve the survival rate of patients with pulmonary metastases [30,35]. Aimin et al [36] have reported a 38.3-month median OS in the solitary metastasis group after lung MWA. We followed up all 32 patients in our study.…”
“…We followed up all 32 patients in our study. The median DFI was 15 months from the time of the primary operation, and the median survival time was 31 months, similar to the reported studies [36]. Belforie et al [19] reported cancer-specific mortalities of 69%, 54% and 49% at 1, 2 and 3 years in 56 patients treated with MWA.…”
Section: Discussionsupporting
confidence: 83%
“…In the present study, the 1-, 2-and 3-year survival rates were 79.5%, 63.1% and 44.4%, respectively. Reported independent predictors of OS include location of primary disease for lung metastasis [37], tumour stage [36], number of metastases [37], tumour size [20,36,37] and extrapulmonary metastasis [38]. In the present study, multivariate analysis showed that tumour size was an independent prognostic factor for survival.…”
Section: Discussionsupporting
confidence: 51%
“…Previous studies have shown that MWA therapy can improve the survival rate of patients with pulmonary metastases [30,35]. Aimin et al [36] have reported a 38.3-month median OS in the solitary metastasis group after lung MWA. We followed up all 32 patients in our study.…”
“…The reported primary technical success rate for MWA ranges from 80 to 100%. 24,39 The lower margin of this technical success rate is compensated by the fact that the ablation can be repeated multiple times until adequate margins are achieved. The reported median time to recurrence was as high as 39.7 months in one study, with strong association with original tumor diameter.…”
Lung cancer is the leading cause of cancer-related mortality worldwide. Eighty-five percent of cases correspond to non-small cell lung cancer (NSCLC) and pivotal nonsurgical options for early-stage disease include percutaneous ablation and stereotactic body radiation therapy (SBRT). Microwave Ablation (MWA) is a locoregional treatment option that has many advantages over radiofrequency ablation and has been able to overcome the limitations of this technique in the treatment of early-stage NSCLC. In this review article, we highlight the current evidence supporting the use of MWA in patients with early-stage NSCLC and discuss the technical considerations of the procedure, including optimal patient selection and planning strategies, as well as the potential complications and reported outcomes. Finally, we mention future trends involving ablation in NSCLC, including its role in combination with SBRT in central tumors, management of post-SBRT local recurrence, and its potential as an adjuvant treatment option for patients with resistance to systemic therapy or in combination with checkpoint inhibitors.
“…The results in the study by Takao Hiraki et al [29] showed that the local control rates of stage I NSCLC after RFA were 72% at 1 year, 63% at 2 years and 63% at 3 years. Amini Zheng et al [30] reported that after MWA, the local progression rates in the tumour with a maximum diameter <3, 3.1-5 and >5 cm were 7.4, 27.4 and 42.3%, respectively. Our data showed the better local control of MWA, which might be ascribed to the much bigger MWA lesion.…”
Microwave ablation has similar therapeutic effect compared with lobectomy for stage I non-small cell lung cancer, but with fewer complication and less pain.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.